Keyword: U.S. Patent & Trademark Office
Allergan took its tribal licensing deal all the way to the Supreme Court, which declined to hear the case.
Celgene's Revlimid cleared a big hurdle as the U.S. Patent and Trademark office declined to kick off a review of its patents.
An appeals court rejected a motion by J&J to issue an injunction against Zytiga generics, potentially opening the market as a patent case plays out.
An appeals court rejected Allergan's attempt to protect Restasis patents with sovereign immunity, clearing the way for generics.
Allergan made countless headlines last year with its scheme to protect Restasis from patent challenge by striking a licensing deal with the Saint Regis Mohawk Tribe. But thanks to a separate federal court decision, the company faces the prospect of early generics anyway.
After a Friday ruling, Allergan's eye drug Restasis has to face the very patent challenge the company sought to prevent.
Johnson & Johnson's prostate cancer drug Zytiga lost a key patent challenge that clears the way for cheap copycats later this year.
Allergan's anticompetitive behavior didn't begin with its tribal licensing deal to protect Restasis from rivals, a new lawsuit alleges.
Allergan CEO Brent Saunders said it was "tenacity," not "desperation," that led the company to enter into the tribal licensing deal.
Mylan and other generics makers urged a Texas judge to call Allergan's Restasis patent deal with the Saint Regis Mohawk Tribe a "sham."